HIGHFDA DRUG

Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge...

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
June 4, 2026
Status
ACTIVE

Quick Facts at a Glance

Recall Date
June 4, 2026
Hazard Level
HIGH
Brands
DULOXETINE, Breckenridge Pharmaceutical, Inc.
Geographic Scope
1 states

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
DULOXETINE, Breckenridge Pharmaceutical, Inc.
Model numbers
Lot: 241180C, Exp. Date April 2027.
UPC codes
51991-746, 51991-747, 51991-748, 51991-750, 51991-746-06, 51991-746-90, 51991-746-05, 51991-747-33 +6 more
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    June 4, 2026

  2. Reported by FDA DRUG

    June 17, 2026

  3. RecallRadar source check

    June 23, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Breckenridge Pharmaceutical, Inc. or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for DULOXETINE recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Full Description

Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10. Generic: DULOXETINE HYDROCHLORIDE; Brand: DULOXETINE. Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Classification: Class II. Quantity: 14,729 bottles.. Distribution: Nationwide within the United States

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: How to Get Refunds and Replacements

Want to Know First?

Get instant alerts for recalls that affect you. Free forever.

Product Classification

Product Details

Model Numbers
Lot: 241180C
Exp. Date April 2027.
UPC Codes
51991-746
51991-747
51991-748
+11 more
Affected States
ALL
Report Date
June 17, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Duloxetine Capsules Recalled Over High N-Nitroso Impurity Risk

Towa Pharmaceuticals recalled 3,397 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations resulting in N-nitroso-duloxetine levels exceeding FDA limits. Consumers must stop using the product immediately.

DULOXETINE
CGMP Deviations;
Read more